April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Purinergic Regulation of Degranulation by Human LAD2 Mast Cells
Author Affiliations & Notes
  • C.T. Leung
    Physiology, School of Medicine, University of Pennsylvania, Philladelphia, Pennsylvania
  • A. Li
    Physiology, School of Medicine, University of Pennsylvania, Philladelphia, Pennsylvania
  • Z.G. Gao
    NIDDK, NIH, Bethesda, Maryland
  • K. Peterson-Yantorno
    Physiology, School of Medicine, University of Pennsylvania, Philladelphia, Pennsylvania
  • K.A. Jacobson
    NIDDK, NIH, Bethesda, Maryland
  • M.M. Civan
    Physiology, School of Medicine, University of Pennsylvania, Philladelphia, Pennsylvania
    Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  C.T. Leung, None; A. Li, None; Z.G. Gao, None; K. Peterson-Yantorno, None; K.A. Jacobson, None; M.M. Civan, None
  • Footnotes
    Support  University of Pennsylvania Research Foundation; NIH Grants EY13624 (M.M.C.); Intramural Research Program of NIDDK, NIH
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2911. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.T. Leung, A. Li, Z.G. Gao, K. Peterson-Yantorno, K.A. Jacobson, M.M. Civan; Purinergic Regulation of Degranulation by Human LAD2 Mast Cells. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2911.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Mast-cell degranulation releases histamine and other products crucial in allergic conjunctivitis. Adenosine receptors (ARs) have been reported to modify degranulation, but observations vary with species, tissue and stimulus. This study tested the roles of ARs in degranulation of human LAD2 mast cells activated immunologically or by C3a complement component.

Methods: : LAD2 cells were gifts from NIAID. Gene expression of the ARs was quantified by real-time PCR. Degranulation was triggered by cross-linking FcεRI anchored IgE or by adding 0.2 µM C3a, and monitored as percentage β-hexosaminidase release. ATP concentrations were measured by the luciferin-luciferase method.

Results: : Relative expression of A2A, A2B and A3 ARs was 1.00, 0.24 and 0.32, respectively, and A1 was undetectable (n=3). The non-selective AR agonist NECA (1 µM) enhanced both C3a-(63 ± 4%; n=76) and immunologically-triggered (54 ± 4%; n=78) degranulation. The selective A2A antagonist SCH 442416 blocked enhancement of C3a- and immunologically-triggered degranulation by ~60% and ~70%, respectively. The A2B antagonist MRS 1754 blocked only enhancement of C3a-degranulation by ~60%. The A3 antagonist MRS 1191 did not significantly reduce either enhancement. The antagonists little affected C3a-stimulated degranulation alone. Addition of all 3 AR antagonists nearly abolished the NECA-enhanced effect of degranulation by both stimuli. Mast cells themselves were not a significant source of adenosine delivery since baseline bath concentration of ATP (29 ±4 nM; n=36) was not increased after stimulation with C3a (n=12), cross-linking FcεRI (n=24) or 50% hypotonicity (n=18).

Conclusions: : LAD2 express ARs in the order A2A>A2B, A3, but A1 was undetectable. Non-selective activation of ARs with NECA enhances degranulation stimulated immunologically or by C3a. Selective AR inhibition reduced the enhancements, with A2A≥A2B>A3. Ecto-enzymatic metabolism of autocrine-released ATP is not a significant source of adenosine. We conclude that mast cell degranulation can be modulated by ecto-enzymatic dephosphorylation of ATP found in inflammatory milieux, largely through A2AR.

Keywords: adenosine • receptors: pharmacology/physiology • conjunctivitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×